Omvoh (Mirikizumab)

Mirikizumab, the active ingredient in Omvoh, is a monoclonal antibody presented as a 100 mg/mL solution for intravenous infusion use. It targets inflammatory pathways and is indicated for the treatment of moderate to severe ulcerative colitis in adult patients. GNH USA supplies Omvoh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialty clinics worldwide.

GNH USA supplies Omvoh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialty clinics worldwide.

Omvoh is a selective interleukin‑23 (IL‑23) inhibitor used in inflammatory bowel disease management.

- Ulcerative colitis: reduces signs and symptoms, achieving clinical remission in many patients. - Crohn’s disease (investigational): evaluated for induction of remission in clinical trials. - Pouchitis: studied as a potential therapy for inflammation of the ileal pouch. - Rheumatoid arthritis (exploratory): assessed in early‑phase studies for disease activity reduction.

Adverse reactions reported with mirikizumab are generally mild to moderate, but serious events can occur.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the infusion site. - Upper respiratory tract infection: nasopharyngitis or mild sinusitis. - Headache: transient and often mild. - Fatigue: general feeling of tiredness. - Nausea: occasional mild gastrointestinal upset. - Diarrhea: loose stools without infection.

Serious or Rare Side Effects: - Severe infections: including opportunistic bacterial, fungal or viral infections. - Hypersensitivity reactions: anaphylaxis, urticaria, or angioedema. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Inflammatory bowel disease flare: paradoxical worsening of disease activity. - Malignancy risk: potential increased risk of certain cancers with long‑term immunosuppression. - Cardiovascular events: rare cases of myocardial infarction or stroke.

When prescribing mirikizumab, clinicians should assess patient history and monitor for specific safety concerns.

- Infection screening: evaluate for active or latent infections before initiation. - Vaccination status: update vaccines, avoiding live vaccines during therapy. - Liver function: monitor transaminases and bilirubin periodically. - Gastrointestinal monitoring: watch for signs of disease flare or new abdominal symptoms. - Pregnancy and lactation: weigh potential benefits against unknown fetal risks. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Mirikizumab may interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: concurrent administration can cause severe infection. - Systemic immunosuppressants (e.g., high‑dose corticosteroids): may amplify infection risk.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., azoles): may require infection surveillance. - Antiviral therapies (e.g., hepatitis B prophylaxis): monitor viral load. - Antibiotics: use judiciously, observing for opportunistic infections.